Coronavirus Vaccines and High Doses of Antivenom
The ups and downs in looking for a coronavirus vaccine are reflected in share price performance. Moderna shares jumped 16% yesterday as the company announced strong trial results, but only last week, shares dropped 20% on delays. You’ll see this short-term pattern repeated many more times.
The race for a cure is on, and with governments waiting to place orders on the first solution that makes it to market, and a fairly short-lived market expected, this is winner takes all.
That’s why volatility in these stocks is so high as investors trade into the names they believe are winning the race daily. There’s no point finishing second. It’s all or nothing. Will Moderna be the one or a pharma giant with more resources?
Boston Scientific isn’t looking for the jackpot coronavirus drug, because it has even cooler assets. It’s got a snake venom unit worth up to one-billion-dollars, developing new antivenom treatments.
You don’t think much about this sort of thing until it’s suddenly the only thing you can think about! It’s a market that never goes away. Boston Scientific is an Invstr community favorite, hosting 98% buyers and only 2% sellers. It’s going to try and sell its antivenom unit to cash out some of these loyal backers. Shares rose 4% on the news!
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.
